SCHEMBL23218215

SCHEMBL23218215

CCOC(=O)Cc1c(OC)cccc1OCc1coc2ccc(Br)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
POLB P06746 2/20 0.40
MAPT P10636 6/20 0.39
MAPK1 P28482 2/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
THRB P10828 2/20 0.36
TP53 P04637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
PTGER1 P34995 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
DPP4 P27487 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852971 1.00 KMT2A (0.40) KMT2AMEN1POLBMAPTMAPK1
SCHEMBL29852755 0.91 THRB (0.40) KMT2AMEN1POLBMAPTMAPK1
SCHEMBL23218028 0.91 THRB (0.40) KMT2AMEN1POLBMAPTMAPK1
SCHEMBL23218641 0.90 PTGER1 (0.39) KMT2AMEN1POLBMAPTMAOA
SCHEMBL23218697 0.88 MAPT (0.40) KMT2AMEN1POLBMAPTMAPK1
SCHEMBL29852717 0.88 MAPT (0.40) KMT2AMEN1POLBMAPTMAPK1
Hexane SCHEMBL31615131 0.86 PTGER1 (0.37) MAPTTHRBNPSR1PTGER1ALDH1A1
Hexane SCHEMBL23219247 0.86 PTGER1 (0.37) MAPTTHRBNPSR1PTGER1ALDH1A1
SCHEMBL23218949 0.86 TBXAS1 (0.41) KMT2AMEN1POLBMAPTTSHR
SCHEMBL23218535 0.83 PTGER1 (0.39) KMT2AMEN1POLBMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB KMT2A 4445/4885MEN1 1819/4885POLB 3530/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB KMT2A 4835/4885MEN1 548/4885POLB 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.